GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy PARIS, Feb. 29, 2016 (GLOBE NEWSWIRE) -- GenSight Biologics S.A. (GenSight), a clinical-stage biotechnology company discovering and developing novel gene therapies for neurodegenerative retinal...